Monoclonal Antibodies

Monoclonal antibodies (mAbs) are identical immunoglobulin molecules manufactured from a single parent B-lymphocyte clone, each engineered to recognize and bind exactly one epitope on a target antigen. The foundational technique was described in 1975 by Georges Köhler and César Milstein at the Medical Research Council Laboratory of Molecular Biology in Cambridge, who fused antibody-producing mouse spleen cells with immortal myeloma cells to create a hybridoma—a cell line that both proliferates indefinitely and secretes a single, uniform antibody. The work earned Köhler, Milstein, and Niels Jerne the 1984 Nobel Prize in Physiology or Medicine. Because the antibodies derive from one clone, they are functionally homogeneous, distinguishing them from polyclonal antibodies, which are a heterogeneous mixture produced by many B-cell lineages in response to multiple epitopes. For UPSC General Studies Paper III, mAbs sit at the intersection of biotechnology, health policy, and indigenous pharmaceutical capacity.

The classical production sequence begins with immunizing a host animal—usually a mouse—with the target antigen, prompting an immune response that generates antigen-specific B cells. The animal's spleen is harvested, and its B cells are fused with myeloma cells using polyethylene glycol or electrofusion. The resulting hybridomas are cultured in a selective HAT medium (hypoxanthine-aminopterin-thymidine), which kills unfused myeloma cells and allows only successfully fused hybrids to survive. Individual hybridomas are then screened, isolated by limiting dilution into single-cell clones, and tested for antibody specificity and affinity. The chosen clone is expanded in bioreactors or ascites fluid, and the secreted antibody is purified by protein-A affinity chromatography. Each step is quality-controlled to ensure the product binds only its intended target.

A central challenge is that purely murine antibodies provoke a human anti-mouse antibody (HAMA) response, limiting repeated dosing. Modern engineering addresses this through progressive humanization. Chimeric antibodies splice mouse variable regions onto human constant regions (denoted by the suffix -ximab, as in rituximab); humanized antibodies retain only the murine antigen-binding loops grafted onto a human framework (-zumab, as in trastuzumab); and fully human antibodies are produced using transgenic mice or phage-display libraries (-umab, as in adalimumab). Newer formats include bispecific antibodies that engage two antigens simultaneously, antibody-drug conjugates that deliver cytotoxic payloads to tumor cells, and nanobodies derived from single-domain camelid antibodies. Recombinant expression in Chinese hamster ovary (CHO) cell lines has largely supplanted hybridoma cultivation for commercial-scale manufacture.

Contemporary applications span oncology, autoimmune disease, and infectious disease. Trastuzumab (Herceptin) targets HER2-positive breast cancer; rituximab treats non-Hodgkin lymphoma and rheumatoid arthritis; adalimumab (Humira) blocks tumor necrosis factor in inflammatory conditions and ranks among the world's highest-grossing drugs. During the COVID-19 pandemic, the US FDA issued Emergency Use Authorizations for monoclonal cocktails including casirivimab-imdevimab (Regeneron) and bamlanivimab. In India, the Department of Biotechnology and Council of Scientific and Industrial Research have prioritized biosimilar mAbs to reduce import dependence; firms such as Biocon, Dr. Reddy's, and Zydus market biosimilar versions of trastuzumab and rituximab, and the Central Drugs Standard Control Organisation (CDSCO) regulates their approval. India approved its first indigenously developed mAb against COVID-19 and continues to expand domestic biopharmaceutical capacity under the BioE3 policy framework announced in 2024.

Monoclonal antibodies must be distinguished from several adjacent concepts. Unlike polyclonal antibodies, which recognize multiple epitopes and vary batch to batch, mAbs are uniform and reproducible. They differ from vaccines, which stimulate the recipient's own immune system to generate antibodies actively; mAbs confer passive immunity by supplying ready-made antibodies that act immediately but wane within weeks. They are also distinct from small-molecule drugs, which are chemically synthesized, orally bioavailable, and far cheaper to produce, whereas mAbs are large protein biologics requiring cold-chain storage and parenteral administration. A biosimilar is not a generic copy but a highly similar version of an off-patent biologic, requiring its own comparative clinical trials because living-cell manufacture precludes exact replication.

Controversies center on cost, access, and regulation. Originator mAbs can cost tens of thousands of dollars per treatment course, raising equity concerns acutely in low- and middle-income countries; biosimilars lower prices but face complex interchangeability and patent-thicket litigation. Cold-chain logistics complicate distribution in tropical settings. Safety issues include cytokine release syndrome, infusion reactions, and immunogenicity. The rapid EUA-based deployment of COVID-19 mAbs exposed a structural weakness: antibodies engineered against one viral variant can lose efficacy as the pathogen mutates, and several authorizations were withdrawn as the Omicron lineage rendered them ineffective. Emerging frontiers include CAR-T adjacencies, mAbs against Alzheimer's amyloid (lecanemab, approved 2023), and engineered antibodies for migraine and cholesterol management.

For the working practitioner—whether a civil-services aspirant, health-ministry desk officer, or trade negotiator—monoclonal antibodies illustrate how biotechnology fuses scientific innovation with strategic and economic policy. They anchor debates over self-reliance in critical pharmaceuticals, intellectual-property flexibilities under the TRIPS Agreement, and the regulatory architecture for biosimilars. India's positioning as a biosimilar manufacturing hub bears directly on global health diplomacy and the affordability of cancer and autoimmune care. Understanding the hybridoma mechanism, the humanization spectrum, and the distinction between active and passive immunity equips officials to assess procurement, pricing, and indigenous research priorities with technical precision rather than generality.